Is Sarepta Therapeutics, Inc. (SRPT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 59.3% / 30% | 53.6% / 30% | 29.6% / 30% | 1.67% / 5% | ✗ NOT HALAL |
| DJIM | 59.3% / 33% | 53.6% / 33% | 29.6% / 33% | 1.67% / 5% | ✗ NOT HALAL |
| MSCI | 31.0% / 33% | 28.1% / 33% | 15.5% / 33% | 1.67% / 5% | ✓ HALAL |
| S&P | 59.3% / 33% | 53.6% / 33% | 29.6% / 33% | 1.67% / 5% | ✗ NOT HALAL |
| FTSE | 31.0% / 33% | 28.1% / 33% | 15.5% / 50% | 1.67% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | -7.4% | |
| Operating Margin | -92.6% | |
| Net Margin | -32.5% | |
| Return on Equity (ROE) | -53.5% | |
| Return on Assets (ROA) | -11.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$205M |
| Free Cash Flow | -$315M |
| Total Debt | $1.0B |
| Debt-to-Equity | 91.1 |
| Current Ratio | 2.3 |
| Total Assets | $3.3B |
Price & Trading
| Last Close | $21.68 |
| 50-Day MA | $18.76 |
| 200-Day MA | $19.65 |
| Avg Volume | 2.6M |
| Beta | 0.5 |
|
52-Week Range
$10.42
| |
About Sarepta Therapeutics, Inc. (SRPT)
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Sarepta Therapeutics, Inc. (SRPT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Sarepta Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Sarepta Therapeutics, Inc.'s debt ratio?
Sarepta Therapeutics, Inc.'s debt ratio is 59.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 31.0%.
What are Sarepta Therapeutics, Inc.'s key financial metrics?
Sarepta Therapeutics, Inc. has a market capitalization of $2.1B, and revenue of $2.2B. The company maintains a gross margin of -7.4% and a net margin of -32.5%. Return on equity stands at -53.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.